Literature DB >> 32639929

Strategic Operational Redesign for Successfully Navigating Prior Authorization Barriers at a Large-Volume Proton Therapy Center.

Eric D Brooks1,2, Matthew S Ning1, Matthew B Palmer3, G Brandon Gunn1,4, Steven J Frank1,4, Aashish K Shah5.   

Abstract

PURPOSE: Prior authorization (PA) can be a resource-intensive barrier to oncologic care. To improve patient access and reduce delays at our large, academic proton therapy center, we implemented a novel payor-focused strategy to efficiently navigate the PA process while eliminating physician burden and reducing inappropriate denials.
METHODS: In 2017, business operations were redesigned to better reflect the insurance process: (1) certified medical dosimetrists (CMDs), with their unique treatment expertise, replaced our historical PA team to function as an effective interface among physicians, patients, and payors; (2) a structured, tiered timeline was implemented to hold payors accountable to PA deadlines; and (3) our PA team provided administrative leadership with requisite insurance knowledge. PA outcomes were compared 6 months before and after the intervention.
RESULTS: After implementation of this multifaceted strategy, the median time to successful appeal (after initial denial of coverage) decreased from 30 to 18 days (P < .001), and the total number of overturned denials increased by 56%. Because of the efficiency of the CMDs, full-time equivalents on the PA team actually decreased by 44%, translating to a 34% reduction in team personnel expenses. Internal referrals increased by 29%, attributable to optimized communication and diminished administrative burden for providers. New treatment starts also increased, resulting in a 37% larger patient census on treatment.
CONCLUSION: Incorporating payor-focused strategies can improve patient access in a cost-effective manner while decreasing time and administrative burden associated with the PA process. These operational concepts can be adapted for other oncologic practice settings facing analogous PA-related obstacles.

Entities:  

Year:  2020        PMID: 32639929      PMCID: PMC8189610          DOI: 10.1200/JOP.19.00533

Source DB:  PubMed          Journal:  JCO Oncol Pract        ISSN: 2688-1527


  14 in total

Review 1.  Utilization management: issues, effects, and future prospects.

Authors:  Thomas M Wickizer; Daniel Lessler
Journal:  Annu Rev Public Health       Date:  2001-10-25       Impact factor: 21.981

2.  Peering into the black box: billing and insurance activities in a medical group.

Authors:  Julie Ann Sakowski; James G Kahn; Richard G Kronick; Jeffrey M Newman; Harold S Luft
Journal:  Health Aff (Millwood)       Date:  2009-05-14       Impact factor: 6.301

3.  US physician practices versus Canadians: spending nearly four times as much money interacting with payers.

Authors:  Dante Morra; Sean Nicholson; Wendy Levinson; David N Gans; Terry Hammons; Lawrence P Casalino
Journal:  Health Aff (Millwood)       Date:  2011-08-03       Impact factor: 6.301

4.  Randomized Trials of Proton Therapy: Why They Are at Risk, Proposed Solutions, and Implications for Evaluating Advanced Technologies to Diagnose and Treat Cancer.

Authors:  Justin E Bekelman; Andrea Denicoff; Jeffrey Buchsbaum
Journal:  J Clin Oncol       Date:  2018-07-09       Impact factor: 44.544

5.  Increasing Burden of Prior Authorizations in the Delivery of Oncology Care in the United States.

Authors:  Nancy U Lin; Harvey Bichkoff; Michael J Hassett
Journal:  J Oncol Pract       Date:  2018-08-20       Impact factor: 3.840

6.  Three ways to make proton therapy affordable.

Authors:  Thomas R Bortfeld; Jay S Loeffler
Journal:  Nature       Date:  2017-09-25       Impact factor: 49.962

7.  The Insurance Approval Process for Proton Radiation Therapy: A Significant Barrier to Patient Care.

Authors:  Matthew S Ning; Daniel R Gomez; Aashish K Shah; Charissa R Kim; Matthew B Palmer; Nikhil G Thaker; David R Grosshans; Zhongxing Liao; Bhavana V Chapman; Eric D Brooks; Chad Tang; David I Rosenthal; Adam S Garden; Steven J Frank; G Brandon Gunn
Journal:  Int J Radiat Oncol Biol Phys       Date:  2018-12-14       Impact factor: 7.038

8.  A Phase 2 Trial of Concurrent Chemotherapy and Proton Therapy for Stage III Non-Small Cell Lung Cancer: Results and Reflections Following Early Closure of a Single-Institution Study.

Authors:  Bradford S Hoppe; Randal Henderson; Dat Pham; James D Cury; Abubakr Bajwa; Christopher G Morris; Harry D'Agostino; Stella Flampouri; Soon Huh; Zuofeng Li; Barry McCook; Romaine C Nichols
Journal:  Int J Radiat Oncol Biol Phys       Date:  2015-11-10       Impact factor: 7.038

9.  Effects of a limiting Medicaid drug-reimbursement benefits on the use of psychotropic agents and acute mental health services by patients with schizophrenia.

Authors:  S B Soumerai; T J McLaughlin; D Ross-Degnan; C S Casteris; P Bollini
Journal:  N Engl J Med       Date:  1994-09-08       Impact factor: 91.245

10.  Variations in Proton Therapy Coverage in the State of Texas: Defining Medical Necessity for a Safe and Effective Treatment.

Authors:  Nikhil G Thaker; Ankit Agarwal; Matthew Palmer; Rosemarie Hontiveros; Stephen M Hahn; Bruce D Minsky; Ronald Walters; John Bingham; Thomas W Feeley; Thomas A Buchholz; Steven J Frank
Journal:  Int J Part Ther       Date:  2016-03-24
View more
  3 in total

Review 1.  Improvements for the Prior Authorization Process for Elective Surgical Procedures at an Academic Medical Center.

Authors:  Karen Y Marble; Genie R Briggs; Xiaoshan Z Gordy
Journal:  Perspect Health Inf Manag       Date:  2022-01-01

2.  Insurance Approval for Definitive Proton Therapy for Prostate Cancer.

Authors:  William M Mendenhall; Eric D Brooks; Stephanie Smith; Christopher G Morris; Curtis B Bryant; Randal H Henderson; Romaine C Nichols; Kathy McIntyre; Stuart L Klein; Nancy P Mendenhall
Journal:  Int J Part Ther       Date:  2021-07-27

3.  Cost-Effectiveness Models of Proton Therapy for Head and Neck: Evaluating Quality and Methods to Date.

Authors:  Danmeng Huang; Steven J Frank; Vivek Verma; Nikhil G Thaker; Eric D Brooks; Matthew B Palmer; Ross F Harrison; Ashish A Deshmukh; Matthew S Ning
Journal:  Int J Part Ther       Date:  2021-06-25
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.